Total pharma venture financing deals for January 2019 worth $1.43bn were announced in the United States, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 17.2% over the previous month and a rise of 10.1% when compared with the last 12-month average of $1.3bn.

The United States held a 71.7% share of the global pharma venture financing deal value that touched $1.99bn in January 2019.

In terms of deal activity, the United States recorded 47 deals during January 2019, marking a decrease of 13% over the previous month and over the 12-month average.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pharma venture financing deals for January 2019: Top deals

The top five pharma venture financing deals accounted for 44.01% of the overall value in January 2019.

The combined value of the top five pharma venture financing deals stood at $629.2m, against the overall value of $1.43bn recorded for the month. The top announced pharma venture financing deal tracked by GlobalData in January 2019 was American International Group, Hercules Capital, Kohlberg Kravis Roberts & Co, Perceptive Advisors, Sequoia Capital Operations, and Viking Global Investors’ $299.2m venture financing of BridgeBio Pharma.

In second place was CMB International Capital’s venture financing of Apollomics for $100m and in third place was Deerfield Management and GV Management Co’s $85m venture financing of Schrodinger.

New Enterprise Associates, Nextech Invest, Perceptive Advisors, RA Capital Management, and Invus Group’s $85m venture financing of Black Diamond Therapeutics and Alexandria Venture Investments, EcoR1 Capital, Polaris Partners, and Samsara BioCapital’s venture financing of Dewpoint Therapeutics for $60m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

Verdict’s parent company GlobalData plc provides business information to 4,000 of the world’s largest companies.